SCHEMBL205073

SCHEMBL205073

COc1cc(Br)ccc1-c1ccc(Br)cc1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 1/20 0.51
TRPV1 Q8NER1 1/20 0.51
ABCB1 P08183 1/20 0.50
ABCC1 P33527 1/20 0.50
ALDH1A1 P00352 4/20 0.46
TDP1 Q9NUW8 2/20 0.46
LMNA P02545 1/20 0.42
MAPT P10636 3/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
PRKDC P78527 1/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
BRD4 O60885 1/20 0.41
S1PR1 P21453 1/20 0.41
EGFR P00533 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5439324 0.92 S100A4 (0.45) S100A4TRPV1ABCB1ABCC1ALDH1A1
SCHEMBL22122225 0.89 ALDH1A1 (0.54) S100A4TRPV1ABCB1ABCC1ALDH1A1
SCHEMBL204357 0.84 S100A4 (0.61) S100A4TRPV1ALDH1A1MAPTKDM4E
SCHEMBL309983 0.83 ALDH1A1 (0.56) S100A4TRPV1ABCB1ABCC1ALDH1A1
SCHEMBL29791349 0.83 ALDH1A1 (0.56) S100A4TRPV1ABCB1ABCC1ALDH1A1
SCHEMBL311157 0.83 ALDH1A1 (0.56) S100A4TRPV1ABCB1ABCC1ALDH1A1
SCHEMBL30193867 0.83 ALDH1A1 (0.56) S100A4TRPV1ABCB1ABCC1ALDH1A1
SCHEMBL47017 0.79 L3MBTL1 (0.55) S100A4TRPV1ABCB1ABCC1ALDH1A1
SCHEMBL10134271 0.78 HTR7 (0.51) S100A4TRPV1ALDH1A1TDP1LMNA
SCHEMBL2088203 0.76 TUBB4A (0.49) S100A4TRPV1ABCB1ABCC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099905-A1 Combinations of drugs for the treatment of neoplasms BORISY ALEXIS 2007-05-03 US claimed
CN-1829509-A Pharmaceutical composition for treating tumors COMBINATORX INC (US) 2006-09-06 CN claimed
EP-1545544-A2 COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS Combinatorx, Incorporated (US) 2005-06-29 EP claimed
US-20050080075-A1 Formulations, conjugates, and combinations of drugs for the treatment of neoplasms COMBINATORX, INC. 2005-04-14 US claimed
WO-2005020913-A2 FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2005-03-10 WO claimed
US-20050054708-A1 Combinations of drugs for the treatment of neoplasms COMINATORX, INCORPORATED 2005-03-10 US claimed
US-20040116407-A1 Combinations of drugs for the treatment of neoplasms COMBINATORX, INC. 2004-06-17 US claimed
WO-2004006842-A2 COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2004-01-22 WO claimed
WO-2004006849-A2 COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2004-01-22 WO claimed
EP-3626716-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-03-25 EP disclosed
US-9981955-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2018-05-29 US disclosed
EP-3309157-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2018-04-18 EP disclosed
EP-3002281-B1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC (US) 2017-09-13 EP disclosed
EP-3002281-B1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC (US) 2017-09-13 EP disclosed
WO-2004006842-A2 COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2004-01-22 WO disclosed
WO-2004006849-A2 COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2004-01-22 WO disclosed
WO-2004002430-A2 COMBINATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS COMBINATORX INCORPORATED (US) 2004-01-08 WO disclosed
EP-1105381-A1 DICATIONIC DIBENZOFURAN AND DIBENZOTHIOPHENE COMPOUNDS AND METHODS OF USE THEREOF The University of North Carolina at Chapel Hill (US) 2001-06-13 EP disclosed
US-6172104-B1 ADMINISTERING TO TREAT PNEUMOCYSTIS CARINII PNEUMONIA THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2001-01-09 US disclosed
WO-2000010990-A2 DICATIONIC DIBENZOFURAN AND DIBENZOTHIOPHENE COMPOUNDS AND METHODS OF USE THEREOF UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2000-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080075-A1 Formulations, conjugates, and combinations of drugs for the treatment of neoplasms ABCB1, SLCO1B3, SLCO1B1 S100A4 1239/4885TRPV1 2803/4885ABCB1 1/4885
US-20070099905-A1 Combinations of drugs for the treatment of neoplasms VHL, NRAS, MYC S100A4 64/4885TRPV1 3480/4885ABCB1 10/4885
US-20050054708-A1 Combinations of drugs for the treatment of neoplasms TYMP, DPYD, DHFR S100A4 471/4885TRPV1 4419/4885ABCB1 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.